



NeuroScientific

BIOPHARMACEUTICALS

ASX:NSB

**ASX ANNOUNCEMENT
18 NOVEMBER 2021**

INVESTOR WEBINAR PRESENTATION

NeuroScientific Biopharmaceuticals Ltd (ASX: **NSB**) (“**NeuroScientific**” or “**the company**”) is pleased to advise shareholders and investors that the Company will be presenting as part of the free Broker Briefing Investor Webinar to be held on Thursday 18 November 2021, 11:30am AEST / 8:30am AWST.

DATE: 18 November 2021

TIME: 11:30am AEST / 8:30am AWST

PRESENTER: Dr Alexandra Andrews, PhD – Director of Operations

WEBINAR LINK: https://zoom.us/webinar/register/WN_yeFPaaH-RuqLDd8Rmg2Uqg

This announcement is authorised by the Board of NeuroScientific Biopharmaceuticals Ltd.

-ENDS-

For more information please contact:

Matthew Liddelow
CEO and Managing Director
ml@neuroscientific.com
+ 61 8 6382 1805

Lucas Robinson
Investor Relations
Corporate Storytime
lucas@corporatestorytime.com
+ 61 408 228 889

About NeuroScientific Biopharmaceuticals Ltd

NeuroScientific Biopharmaceuticals Limited (ASX: NSB) is a company developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The company’s product portfolio includes EmtinB™, a therapeutic peptide initially targeting Alzheimer’s disease and glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn) which have demonstrated similar therapeutic potential as EmtinB™. For more information, please visit www.neuroscientific.com

About EmtinB™


EmtinB™ is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinB™ is modelled on a specific

active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body's innate immune response to cell injury.

Our preclinical research has established that EmtinB™ is highly specific and selective for its target receptor, safe and well tolerated at high concentrations, and is able to penetrate the blood brain barrier. A series of Phase I clinical studies will be conducted to establish the safety profile of EmtinB™ in humans.



NOVEL DRUG THERAPIES FOR NEURODEGENERATIVE CONDITIONS

Company Presentation
November 2021



NeuroScientific

BIOPHARMACEUTICALS



NeuroScientific
BIOPHARMACEUTICALS

ASX:NSB

DISCLAIMER

The purpose of the presentation is to provide an update of the business of NeuroScientific Biopharmaceuticals Ltd (“NeuroScientific”, or “the Company”). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Further information is available upon request.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside NeuroScientific’s control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and NeuroScientific’s current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by NeuroScientific. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.



COMPANY SNAPSHOT

NOVEL LEAD COMPOUND

- Alzheimer's disease – global prevalence 55M¹, high unmet need
- Multiple Sclerosis – US\$27 billion treatment market ², unmet need for progressive MS
- Glaucoma – 76M global prevalence³, 2nd lead cause of blindness

ADDRESSING UNMET NEED IN NEURODEGENERATION

- EmtinB™ - potential first in-class therapeutic for neurodegenerative conditions
- Potential disease modifying therapeutic
- Low potential for off-target effects

SUBSTANTIAL SAFETY & EFFICACY DATA

- >40 studies completed to date
- Preclinical efficacy data in models of Alzheimer's disease, Multiple Sclerosis, Glaucoma and Spinal Cord Injury.
- Large body of published literature to support MOA

WELL FUNDED FOR PHASE 1 PROGRAMS

- Clinical studies in 2022 – First in Human Phase 1 for Neurology indications and First in Patient for Phase 1 for glaucoma
- \$12.3M cash on hand

CORPORATE OVERVIEW (ASX: NSB)

CAPITAL STRUCTURE

ASX code	NSB
Shares on issue	143.5M
Price (17/11/21)	\$0.36
Market cap	\$53M
McRae Investments	18%
Swiss based fund	9.0%
Executive Management	5.0%

FINANCIALS

- IPO on ASX July 2018 (ASX: NSB)
- ~ \$12.3M cash on hand
- Funded through to completion of current Phase I clinical program
- McRae Investments and AlphaSwiss Partners significant shareholders



LEADERSHIP AND MANAGEMENT



PAUL RENNIE, MBM, MSTC
NON-EXECUTIVE CHAIRMAN

Founding and current CEO of Paradigm Biopharmaceuticals (ASX:PAR). Former COO and Executive VP New Product Development at Mesoblast Ltd (ASX:MSB).



MATT LIDDELOW, MPHARM
MD + CEO

14+ years experience commercialising medical devices and pharmaceuticals for multi-national companies including AstraZeneca.



DR ANTON UVAROV, PhD, MBA
EXECUTIVE DIRECTOR + CSO

Founding director of Actinogen Medical (ASX:ACW) an advanced Alzheimer's biotechnology company. Former Equities Analyst with Citigroup, US



STEPHEN QUANTRILL, MBA
NON-EXECUTIVE DIRECTOR

20+ years experience in corporate advisory and company directorship, Executive Chairman of McRae Investments.



ABBY MACNISH, CFA
Company Secretary & CFO



DOUGAL THRING, MSc
VP Clinical Development



DR ALEXANDRA ANDREWS, PhD
Director of Operations

MARKETS

- **Neurodegenerative Disease market** valued at ~USD 39.24 billion in 2020 is expected to witness a revenue of USD 44.90 billion in 2026¹
- ~ **55 million** people worldwide currently have dementia and there are ~ 10 million new cases every year; Alzheimer disease affects about **60-70%** of them²
- The global multiple sclerosis drugs market value is \$27.38 billion in 2021³
- The total lifetime costs on individual MS patients exceed \$4 million⁴

Biogen's Aduhelm win opened up market frenzy for Alzheimer's-focused companies

by Annalee Armstrong | Jul 15, 2021 9:12am



Source: <https://www.fiercebiotech.com/biotech/biogen-s-aduhelm-win-opened-up-market-frenzy-for-alzheimer-s-focused-companies>

EMTINB™ PRECLINICAL DATA

- Nerve regeneration (including significant results in spinal injury model)
- Reduction in neuroinflammation
- Neuroprotection in cell survival models >90%
- Proliferation of myelin in Multiple Sclerosis model
- Slowed cognitive decline in Alzheimer's disease animal models
- Slowed glaucoma-induced damage to the optic nerve in animal model
- Advanced safety program in animals, including non-human primates



EMTINB™ DEVELOPMENT PLAN

2021

2022

Completion of
neurology IND-enabling
studies
Q4 2021

Ph1 neurology
study
Q1 2022

Complete ocular
IND-enabling studies
Q1 2022

Ph1 glaucoma
study
H1 2022

Ph2 Neurology study
Q4 2022

Ph2 glaucoma
study

Please note:

Indicative timeline only and subject to change due to the Company relying on independent contract service providers to perform our research.

PARTNERS AND COLLABORATIONS

NON-CLINICAL RESEARCH



CLINICAL RESEARCH



MANUFACTURING



SCIENTIFIC ADVISORY



Dr Frank Bonner, PhD FBTS
Former Director, Non-clinical R&D, Novartis



Prof. Dao-Yi Yu MD FRANZCO
Head, Physiology & Pharmacology Research,
Lions Eye Inst. Australia




Clin Prof. Allan Kermode MBBS MD FRACP FRCP
Head, Neurology & Neurophysiology, SCG Hospital,
WA Australia. Head, Demyelinating Disease
Research, Perron Inst. Australia



Dr Peter Hnik, MD MHSc
Ophthalmologist, President of Cliniscape
Consulting, Former Chief Medical Officer of
ICO Therapeutics Inc. Canada

SUMMARY OVERVIEW

- Drug development company with advanced preclinical lead candidate - EmtinB™
 - Funded through to completion of Phase I program
 - Potential for multiple treatment indications (pipeline in a product)
 - Peptide based drug with advanced safety program, including non-human primates
 - Transitioning EmtinB™ to clinical development in 2022
- **EmtinB™ preclinical data has demonstrated:**
 - Neuroprotection, axonal regeneration, decreased neuroinflammation
 - Regeneration of myelin in Multiple sclerosis model
 - Slowed cognitive decline in Alzheimer's disease
 - Protected & restored optic nerve in glaucoma



FOR MORE INFORMATION:

Matt Liddelow

CEO & Managing Director
ml@neuroscientific.com

Alex Andrews

Director of Operations
aa@neuroscientific.com

www.neuroscientific.com



NeuroScientific
BIOPHARMACEUTICALS

ASX:NSB